Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Biohaven Ltd.NYSE: BHVN
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$132.3M, compared with -$195.91M a year earlier. Trailing-twelve-month EBITDA was -$574.94M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +13.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$132.3M-3.4% QoQ
- Last fiscal yearDec 2025
- -$727.46M+13.2% YoY
- LTMJun 2026
- -$574.94M+24.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.5% | +100.0% | +67.5 pp |
| 1 year | +13.2% | +100.0% | +86.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (727.46M) USD
- Year-over-year change
- +13.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (727.46M) | +13.2% |
| FY2024 | 2024-12-31 | (837.83M) | -108.1% |
| FY2023 | 2023-12-31 | (402.64M) | +29.2% |
| FY2022 | 2022-12-31 | (568.46M) | -169.4% |
| FY2021 | 2021-12-31 | (211.04M) | — |
EBITDA vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.1% is the 5th highest of 11, against a peer median of -19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.13M USD | +1163.1% | — | 14.7% | |
| LTM Mar 2026 | $6.24M USD | +2711.1% | — | 1.6% | |
| LTM Mar 2026 | -$81.06M USD | -24.0% | — | — | |
| LTM Sep 2026 | -$138.65M USD | +34.7% | — | 204.3% | |
| LTM Sep 2026 | -€184.94M EUR | -15.5% | — | — | |
| LTM Sep 2026 | -$284.54M USD | -45.7% | — | — | |
| LTM Sep 2026 | -$305.37M USD | -38.1% | — | 272652.7% | |
| LTM Mar 2026 | -$384.61M USD | +25.4% | — | 581.9% | |
| LTM Jun 2026 | -$393.82M USD | -87.1% | — | — | |
| LTM Mar 2026 | -$408.44M USD | -151.5% | — | — | |
| LTM Jun 2026 | -$574.94M USD | +24.1% | — | — | |
| Peer median (excluding BHVN) | — | -19.7% | — | 204.3% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.